|
|
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
Bertrand Coiffier
,
Catherine Thieblemont
,
Sophie de Guibert
,
Jehan Dupuis
,
Vincent Ribrag
et al.
Journal articles
hal-01295660v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Management and outcome of primary CNS lymphoma in the modern era: An LOC network study
Caroline Houillier
,
Carole Soussain
,
Hervé Ghesquières
,
Pierre Soubeyran
,
Olivier Chinot
et al.
Journal articles
hal-02442415v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Sophie Langner-Lemercier
,
Caroline Houillier
,
Carole Soussain
,
Hervé Ghesquières
,
Olivier Chinot
et al.
Journal articles
hal-01290413v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Vincent Ribrag
,
Jehan Dupuis
,
Herve Tilly
,
Franck Morschhauser
,
Fabrice Laine
et al.
Journal articles
hal-01068681v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA
Roch Houot
,
Carole Soussain
,
Hervé Tilly
,
Corinne Haioun
,
Catherine Thieblemont
et al.
Journal articles
hal-01295653v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
Roberta Di Blasi
,
Steven Le Gouill
,
Emmanuel Bachy
,
Guillaume Cartron
,
David Beauvais
et al.
Journal articles
hal-03903472v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma
Cédric Ménard
,
Delphine Rossille
,
Joelle Dulong
,
Tien-Tuan Nguyen
,
Ilenia Papa
et al.
Journal articles
hal-03267824v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
Ciara L. Freeman
,
Franck Morschhauser
,
Laurie Sehn
,
Mark Dixon
,
Richard Houghton
et al.
Journal articles
hal-01275480v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Performance of CT Compared with F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
Fatima-Zohra Mokrane
,
Aiping Chen
,
Lawrence H Schwartz
,
Franck Morschhauser
,
Apasia Stamatoullas
et al.
Journal articles
hal-02569415v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
Emilie Reboursiere
,
Fabien Le Bras
,
Charles Herbaux
,
Emmanuel Gyan
,
Aline Clavert
et al.
Journal articles
hal-01475957v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
Franck Morschhauser
,
Kamal Bouabdallah
,
Stephan Stilgenbauer
,
Catherine Thieblemont
,
Sophie de Guibert
et al.
Journal articles
hal-02635130v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
Christophe Bonnet
,
Jehan Dupuis
,
Hervé Tilly
,
Thierry Lamy
,
Christophe Fruchart
et al.
Journal articles
hal-03660656v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag
,
Serge Koscielny
,
Jacques Bosq
,
Thibaut Leguay
,
Olivier Casasnovas
et al.
Journal articles
inserm-01419476v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study.
Mira Tout
,
Olivier Casasnovas
,
Michel Meignan
,
Thierry Lamy
,
Franck Morschhauser
et al.
Journal articles
hal-01547802v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC
Loic Ysebaert
,
Roch Houot
,
Ibrahim Yakoub-Agha
,
Franck Morschhauser
,
Charles Herbaux
et al.
Blood, 2015, 126 (23), pp.3979-3979
Journal articles
hal-01290424v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
Guillaume Cartron
,
Sophie de Guibert
,
Marie-Sarah Dilhuydy
,
Franck Morschhauser
,
Veronique Leblond
et al.
Journal articles
hal-01147035v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma a phase II LYSA study
Roch Houot
,
Guillaume Cartron
,
Fontanet Bijou
,
Sophie de Guibert
,
Gilles A Salles
et al.
Journal articles
hal-01903056v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies
Laurent Dercle
,
Fatima-Zohra Mokrane
,
Jean Marc Schiano de Colella
,
Apasia Stamatoullas
,
Franck Morschhauser
et al.
Journal articles
hal-02119287v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
Aurore Perrot
,
Hélène Monjanel
,
Reda Bouabdallah
,
Philippe Quittet
,
Clémentine Sarkozy
et al.
Journal articles
hal-01259439v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment
Dang-Nghiem Vo
,
Catherine Alexia
,
Nerea Allende-Vega
,
Franck Morschhauser
,
Roch Houot
et al.
Journal articles
hal-01780378v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Early F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab
Aiping Chen
,
Fatima-Zohra Mokrane
,
Lawrence Schwartz
,
Franck Morschhauser
,
Apasia Stamatoullas
et al.
Journal articles
hal-02364994v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Emmanuel Bachy
,
Roch Houot
,
Franck Morschhauser
,
Anne Sonet
,
Pauline Brice
et al.
Journal articles
hal-00933219v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA
Steven Le Gouill
,
Hervé Ghesquieres
,
Lucie Obéric
,
Franck Morschhauser
,
Herve Tilly
et al.
Journal articles
hal-03122586v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Franck Morschhauser
,
Steven Le Gouill
,
Pierre Feugier
,
Sarah Bailly
,
Emmanuelle Nicolas-Virelizier
et al.
Journal articles
hal-02586078v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|